Search

Search Constraints

You searched for: Author/Creator Bloomquist, Erik

Search Results

2. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Issue 2 (February 2020)

3. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer. Issue 11 (10th April 2022)

4. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. (20th October 2020)

5. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA‐Mutated Metastatic Castrate‐Resistant Prostate Cancer. (17th November 2020)

6. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Issue 11 (November 2021)

7. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Issue 8 (2nd April 2021)

8. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy. (7th October 2015)

9. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non‐Small Cell Lung Cancer Following Disease Progression On or After Platinum‐Based Chemotherapy. (7th October 2015)

10. U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission. (24th April 2019)